Literature DB >> 3930479

Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants.

C M Hekman, D J Loskutoff.   

Abstract

Conditioned medium from cultured bovine aortic endothelial cells contains an inactive plasminogen activator inhibitor (PAI). This latent PAI can be "activated" with denaturants. For example, less than 0.01 units/microliter of PAI activity was detected in untreated conditioned medium, but medium treated with sodium dodecyl sulfate (1.7 mM), guanidine HCl (4 M), urea (12 M) or KSCN (6 M) contained 0.9, 1.9, 0.8, and 0.5 units/microliter, respectively. This effect was dose-dependent with respect to the particular reagent used, and the same concentration of reagent which induced PAI activity also stimulated the ability of a component in conditioned medium to form sodium dodecyl sulfate-stable complexes with exogenously added plasminogen activators. Neither activity was stimulated by extensive dialysis or by treatment with NaCl (5 M), Na2SO4 (2.8 M), or dicetyl phosphate (0.1%). Analysis of treated and untreated conditioned medium by gel filtration revealed that the latent and active PAIs migrated with apparent Mr values of 30,000 and 50,000, respectively. Thus, "activation" is associated with an increase in the apparent Mr of the molecule. These observations suggest that activation does not result from the removal of either a small dialyzable component from the medium, or of a large Mr component that is bound to the latent PAI. Other possible mechanisms of activation are discussed. We recently isolated an active PAI from bovine endothelial cells (van Mourik, J.A., Lawrence, D.A., and Loskutoff, D.J. (1984) J. Biol. Chem. 259, 14914-14921). Monospecific antiserum to this active PAI selectivity immunoprecipitated the latent PAI from conditioned medium. These results indicate that the two PAIs are immunologically related and suggest that the latent form is converted into the active form by the sodium dodecyl sulfate present during the purification.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930479

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  87 in total

1.  Bypassing the kinetic trap of serpin protein folding by loop extension.

Authors:  H Im; H Y Ahn; M H Yu
Journal:  Protein Sci       Date:  2000-08       Impact factor: 6.725

Review 2.  Molecular basis of thrombolytic therapy.

Authors:  H R Lijnen; D Collen
Journal:  J Nucl Cardiol       Date:  2000 Jul-Aug       Impact factor: 5.952

3.  Extending the capabilities of targeted molecular dynamics: simulation of a large conformational transition in plasminogen activator inhibitor 1.

Authors:  P Krüger; S Verheyden; P J Declerck; Y Engelborghs
Journal:  Protein Sci       Date:  2001-04       Impact factor: 6.725

4.  Transforming growth factor-ßs as modulators of pericellular proteolytic events.

Authors:  J Keski-Oja; J Lohi; M Laiho
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

5.  Functional display of proteins, mutant proteins, fragments of proteins and peptides on the surface of filamentous (bacterio) phages: A review.

Authors:  H Pannekoek; M van Meijer; H Gaardsvoll; A J van Zonneveld
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

6.  Lack of effect of thrombin on fibrin(ogen)-endothelial cell interaction.

Authors:  E Réganon; V Vila; V Martínez-Sales; J Aznar
Journal:  Cytotechnology       Date:  1995-06       Impact factor: 2.058

7.  Butyrate stimulates tissue-type plasminogen-activator synthesis in cultured human endothelial cells.

Authors:  T Kooistra; J van den Berg; A Töns; G Platenburg; D C Rijken; E van den Berg
Journal:  Biochem J       Date:  1987-11-01       Impact factor: 3.857

8.  The length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor-1.

Authors:  Yu-Ran Na; Hana Im
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

Review 9.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

10.  Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension?

Authors:  Daniel I Simon; Norman M Simon
Journal:  Circulation       Date:  2013-10-03       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.